Experience with paclitaxel-eluting lnfinnium coronary stents

Asian Cardiovascular and Thoracic Annals

Volumn 16, Issue 6, 2008, Pages 454-458

  Ostovan, Mohammad A ^a   Mollazadeh, Reza ^a   Kojuri, Javad ^a   Mirabadi, Mohammad ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; ELECTROCARDIOGRAPHY; FEMALE; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RESTENOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THROMBOSIS;

EID: 58249098564     PISSN: 02184923     EISSN: None     Source Type: Journal    
DOI: 10.1177/021849230801600605     Document Type: Article

References (19)

1. Grüntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979;301:61-8.
2. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty N Engl J Med 1987;316:701-6.
3. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
4. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents [Review]. N Engl J Med 2006;354:483-95.
5. Costa MA, Simon DI. Molecular basis of restenosis and drug eluting stents. Circulation 2005;111:2257-73.
6. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995;332:1004-14.
7. Axel DI, Kunert W, Goggelmann C, Oberhoff M, Herdeg C, Kuttner A, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997;96:636-45.
8. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42.
9. Cutlip DE, Chauhan MS, Baim DS, Ho KK, Popma JJ, Carrozza JP, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol 2002;40:2082-9.
10. Campeau L. Grading for angina pectoris. Circulation. 1976;54:522-3.
11. Braunwald B. Unstable angina: a classification. Circulation 1989;80:410-4.
12. Ellis SG, Colombo A, Grube E, Popma J, Koglin J, Dawkins KD, et al. Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years. J Am Coll Cardiol 2007;49:1043-51.
13. Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A, et al. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation 2005;112:3306-13.
14. Serruys PW, Ormiston JA, Sianos G, Sousa JE, Grube E, den Heijer P, et al. Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial. J Am Coll Cardiol 2004;44:1363-7.
15. Lansky AJ, Costa RA, Mintz GS, Tsuchiya Y, Midei M, Cox DA, et al. Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation 2004;109:1948-54.
16. Ong AT, Serruys PW. Technology insight: an overview of research in drug-eluting stents. Nat Clin Pract Cardiovasc Med 2005;2:647-58.
17. Bakhai A, Stone GW, Mahoney E, Lavelle TA, Shi C, Berezin RH, et al. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial. J Am Coll Cardiol 2006;48:253-61.
18. Lagerqvist B, James SK, Stenestrand U, Lindbäck J, Nilsson T, Wallentin L, SCAAR Study Group. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-19.
19. Vranckx P, Serruys PW, Gambhir S, Sousa E, Abizaid A, Lemos P, et al. Biodegradable-polymer-based, paclitaxel-eluting Infinnium™ stent: 9-month clinical and angiographic follow-up results from the SIMPLE II prospective multi-centre registry study. Eurointerv 2006;2:310-7. Available at: http://www.smtpl.com/images/ EIJ_No7_SIMPLE_II_9M_FU_Vranckx_FINAL.pdf